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Abstract  
Purpose. ESR1 mutations are acquired frequently in hormone receptor positive 
(HR+) metastatic breast cancer after prior aromatase inhibitors (AI). We assessed 
the clinical utility of baseline ESR1 circulating tumor DNA analysis in the two phase 
III randomised trials of fulvestrant versus exemestane. 
 
Patients and Methods. The phase III EFECT and SoFEA trials randomised patients 
with HR+ metastatic breast cancer who had progressed on prior non-steroidal AI, 
between fulvestrant 250mg and exemestane. Baseline serum samples from 227 
patients in EFECT, and baseline plasma from 161 patients in SoFEA, were analysed 
for ESR1 mutations by digital PCR. The primary objectives were to assess the 
impact of ESR1 mutation status on progression-free and overall survival in a 
combined analysis of both studies. 
 
Results. ESR1 mutations were detected in 30% (151/383) baseline samples. In 
patients with ESR1 mutation detected, PFS was 2.4 months (95%CI,2.0-2.6) on 
exemestane and 3.9 months (95%CI,3.0-6.0) on fulvestrant (HR=0.59, 95%CI,0.39-
0.89; p=0.01). In patients without ESR1 mutations detected, PFS was 4.8 months 
(95%CI,3.7-6.2) on exemestane and 4.1 months (95%CI,3.6-5.5) on fulvestrant 
(HR=1.05, 95%CI,0.81-1.37; p=0.69). There was an interaction between ESR1 
mutation and treatment (p=0.02). Patients with ESR1 mutation detected had one-
year overall survival of 62% (95%CI,45%-75%) on exemestane and 80% 
(95%CI,68%-87%) on fulvestrant (p=0.04, restricted mean survival analysis).  
Patients without ESR1 mutations detected has one-year overall survival of 79% 
(95%CI,71%-85%) on exemestane and 81% (95%CI,74%-87%) on fulvestrant 
(p=0.69).  
 
Conclusions. Detection of ESR1 mutations in baseline ctDNA associated with 
inferior progression-free and overall survival in patients treated with exemestane 
versus fulvestrant.  
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Statement of translational relevance 
 
In patients previously treated with an aromatase inhibitor, detection of ESR1 
mutations in ctDNA analysis identified patients who have worse overall survival if 
treated with exemestane instead of fulvestrant. For patients with acquired ESR1 
mutations further AI therapy is not appropriate, and analysis of ctDNA may be 
considered when selecting endocrine therapy backbone in patients progressing after 
prior AI therapy. 
 
 
Introduction 
Mutations in the oestrogen receptor gene (ESR1) are acquired frequently in 
metastatic hormone receptor positive breast cancer[1, 2]. Mutations are selected in 
the cancer as a mechanism of clinical acquired resistance to prior aromatase 
inhibitor therapy, acquired relatively rarely through tamoxifen[3, 4]. ESR1 mutations 
are acquired most frequently when aromatase inhibitors are used to treat advanced 
breast cancer[5], are more frequently selected in cancers that progress after 
sensitivity to prior aromatase inhibitor therapy, and relatively rare in patients with 
intrinsic endocrine resistance[3]. This presents challenges in the identification of 
ESR1 mutations in standard clinical practice, as although biopsy of a recurring breast 
cancer is now commonplace, repeat biopsy after initial treatment is rarely performed.  
Multiple studies have shown that ESR1 mutations can be identified at high frequency 
in the plasma, in the circulating tumor DNA (ctDNA), of patients after progression on 
aromatase inhibitor therapy[3, 6, 7]. 
 
Multiple sequential lines of endocrine based therapy is a standard of care for 
advanced hormone receptor positive cancer, especially in patients whose cancer 
shows sensitivity to prior or first line hormone therapy[8]. Two phase III trials 
investigated the optimal second line endocrine therapy, randomising patients 
progressing on a non-steroidal aromatase inhibitor between fulvestrant 250mg and 
exemestane, the SoFEA[9] and EFECT[10] studies. In prior analysis we analysed 
ESR1 mutations in baseline plasma from the SoFEA trial. Patients 
with ESR1 mutations had improved progression-free survival (PFS) after taking 
fulvestrant (n=45) compared with exemestane (n=18; hazard ratio [HR]= 0.52; 95% 
CI,0.30 to 0.92; P=.02), whereas patients with wild-type ESR1 had similar PFS after 
receiving either treatment (HR=1.07; 95% CI,0.68 to 1.67; P=.77)[3].  Baseline serum 
samples were available from EFECT, with no plasma samples available. Serum 
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samples present challenges for ctDNA analysis due to release of lymphocyte DNA 
during clotting[11], although in prior research we have shown that release of wild-
type DNA does not substantially effect results of ctDNA analysis with digital PCR[3]. 
 
To assess the clinical utility of ESR1 mutation analysis in ctDNA, we analysed 
baseline ESR1 mutation status in patients entering the EFECT study, and then 
performed a combined analysis of SoFEA and EFECT to investigate the interaction 
between ESR1 mutation status and relative benefit of second line endocrine 
therapies, and the impact of ESR1 mutation status on overall survival (OS) on 
second line endocrine therapies. 
 
Methods 
Study designs 
The EFECT study was a randomised placebo controlled double-dummy phase III trial 
conducted in post-menopausal women with advanced hormone receptor–positive 
breast cancer who had previously progressed on a non-steroidal aromatase inhibitor. 
Patients were randomized between fulvestrant 250mg with a loading dose (500 mg 
intramuscularly on day 1, followed by 250 mg on days 15 and 29, then every 28 
days) or exemestane 25 mg. Baseline serum was available in 227 patients of 693 
patients enrolled (33%, Figure 1). The subset of patients with baseline serum 
available had similar baseline characteristics and outcome to patients without 
samples (Supplementary tables 1 and 2).  
 
The SoFEA study was a multicenter, randomized phase III trial in postmenopausal 
women with advanced, hormone receptor–positive breast cancer who had 
demonstrated prior sensitivity to prior non-steroidal AIs, defined as relapse or 
progression after taking adjuvant treatment for at least 12 months or as first-line 
metastatic treatment for at least 6 months[9]. Patients were assigned fulvestrant at 
the same dosing schedule as EFECT plus anastrozole 1 mg, fulvestrant plus 
placebo, or exemestane 25 mg. Both fulvestrant groups were merged for analysis, 
and ESR1 mutations were analysed in 161 baseline plasma samples as previously 
described[3]. 
 
Both EFECT and SoFEA were approved by ethical or institutional review boards as 
detailed previously [9][10], carried out as per the Declaration of Helsinki, and written 
informed consent was supplied by all participants. 
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ESR1 mutation analysis 
For EFECT baseline serum samples analysis of ESR1 mutations was conducted 
essentially as previously described[3], blinded to clinical results. Multiplex digital PCR 
was used as the analysis method, a method that is largely unaffected by 
contamination of the sample with lymphocyte DNA[3] (Supplementary figure 1). DNA 
was extracted from up to 1 ml of baseline samples and analysed by droplet digital 
PCR on a QX200 system with two multiplex digital PCR assays; multiplex 1 included 
c.1138G.C(E380Q), c.1607T.G(L536R), c.1610A.G(Y537C), and c.1613A.G(D538G; 
dHsaMDXE91450042); multiplex 2 included c.1387T.C(S463P), c.1609T.A(Y537N), 
and c.1610A.C(Y537S; dHsaMDXE65719815).  
 
Statistical analysis 
The combined analysis had two primary objectives, to assess whether there was an 
interaction on progression-free survival between ESR1 mutation status and treatment 
randomisation between exemestane and fulvestrant, and to assess overall survival in 
patients with baseline ESR1 mutations detection. The primary endpoint of EFECT 
was time to progression (TTP, defined as objective disease progression or death) 
and the primary endpoint of SoFEA was progression-free survival (PFS, defined as 
objective disease progression, second primary cancer necessitating a change in 
systemic treatment, or death), both using RECIST 1.0. The primary endpoints of the 
combined analysis was progression-free survival (defined as in the original trial) and 
overall survival, in the subset of patients with successful mutation analysis and with 
treatment randomly assigned on an intention to treat basis. ESR1 mutation analysis 
was retrospective, not conceived in the original study protocols as they predated the 
discovery of ESR1 mutations as a frequent mechanism of AI resistance. 
 
The relationship between baseline ESR1 mutation status and PFS and OS was 
assessed with a Cox proportional hazards regression model along with an interaction 
test to explore differential effects between ESR1 mutation status and trial treatment 
where relevant. All analyses were stratified by trial. The proportionality assumption of 
the Cox models was tested with Schoenfeld residuals. As overall survival analysis in 
the ESR1 mutation detected group was shown to be non-proportional, a restricted 
mean survival analysis with a cut-off of 24 months was also used for OS analysis. 
Secondary analyses included the association between detection of ESR1 mutations 
and clinical and pathological variables. All P values were two sided with a 
significance level of 0.05. All statistical analyses were performed with Stata (version 
13.1; STATA, College Station, TX). 
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 Results  
ESR1 mutation analysis in EFECT 
To enable a combined analysis of EFECT and SoFEA, we first analysed ESR1 
mutation status in baseline serum samples from EFECT (Supplementary figure 2). 
ESR1 mutations were successfully analysed in 98% (222/227) of patients with 
baseline serum samples, with ESR1 mutations detected in 23.4% (52/222) samples. 
(Supplementary figure 3). 
 
ESR1 mutations and progression-free survival in the combined analysis 
The combined analysis of SoFEA and EFECT comprised a total of 383 patients with 
baseline sample ESR1 ctDNA results (Figure 1 and Supplementary table 3), with 326 
PFS events. ESR1 mutations were detected in 30% (115/383) baseline samples 
overall, more frequently in patients with sensitivity to prior AI as defined by the 
original trials (p=0.02) and by setting and time on prior AI therapy (p=0.01) (Table 1).  
In patients with an ESR1 mutation detected, median PFS was 2.4 months 
(95%CI,2.0-2.6) on exemestane and 3.9 months (95%CI,3.0-6.0) on fulvestrant 
(HR=0.59, 95%CI,0.39-0.89, p=0.01). In patients without ESR1 mutations detected, 
PFS was 4.8 months (95%CI,3.7-6.2) on exemestane and 4.1 months (95%CI,3.6-
5.5) on fulvestrant (HR=1.05, 95%CI,0.81-1.38, p=0.69) (Figure 2). There was a 
statistically significant interaction between treatment randomisation and ESR1 
mutation status (interaction p=0.02). 
 
In a multivariable analysis, ESR1 mutation status was associated with shorter PFS 
(HR=1.96 95% CI,1.34-2.86, p=0.001), and an interaction with allocated treatment 
remained significant (p=0.05, Table 2). Older age, bone-only disease, and a period of 
>5 years from initial diagnosis to study entry were associated with longer PFS (Table 
2). 
 
Patients with D538G, Y537X, and E380Q/S463P mutations detected in ctDNA had 
similar progression free survival improvement with fulvestrant compared to 
exemestane (Supplementary Figure 4 and 5). Patients with monoclonal ESR1 
mutations had median PFS on fulvestrant 3.6 months (95% CI,2.7-5.7, N=70) and 
with polyclonal ESR1 mutations had median PFS on fulvestrant 6.6 months (95% 
CI,2.9-11.7, N=42) (Supplementary Figure 6).  
 
ESR1 mutations and objective response in the combined analysis 
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In patients with ESR1 mutations detected objective response rate on fulvestrant was 
9.5% (4/42, 95%CI: 2.7-22.6) and on exemestane was 0.0% (0/36, 95%CI: 0-9.7, 
Fisher's exact p=0.12).  In patients without ESR1 mutations detected objective 
response rate on fulvestrant was 9.6% (9/94, 95%CI: 4.5-17.4) and on exemestane 
was 8.7% (9/103, 95%CI: 4.1-15.9, Fisher's exact p=1.0). In patients with ESR1 
mutations detected clinical benefit rate on fulvestrant was 31.0% (13/42, 95%CI: 
17.6-47.1) and on exemestane was 22.2% (8/36, 95%CI: 10.1-39.2, Fisher's exact 
p=0.45).  In patients without ESR1 mutations detected clinical benefit rate on 
fulvestrant was 37.2% (35/94, 95%CI: 27.5-47.8) and on exemestane was 41.7% 
(43/103, 95%CI: 32.1-51.9, Fisher's exact p=0.56).   
 
 
ESR1 mutations and adverse short-term overall survival  
We investigated the association between ESR1 mutation status and overall survival 
in the combined analysis, with a total of 204 deaths. In patients without ESR1 
mutations detected, median OS was 23.0 months (95%CI,19.2-25.6) on exemestane 
and 25.8 months (95%CI,22.1-29/9) on fulvestrant (HR=0.89, 95%CI,0.64-1.23, 
p=0.49) (Figure 3). In patients with ESR1 mutation detected, median OS was 18.0 
months (95%CI,6.8-27.0) on exemestane and 21.2 months (95%CI,18.3 - 26.1) on 
fulvestrant (HR=0.85, 95%CI,0.51-1.40, p=0.52). However, Cox’s proportional 
hazards assumption was violated for patients with ESR1 mutations detected 
(proportionality assumption rho=0.22, chi2=3.86, p=0.049), suggesting non-
proportional hazards. We therefore repeated the OS analysis utilising a restricted 
mean survival model. In patients with ESR1 mutations detected, patients on 
exemestane had worse OS compared with those on fulvestrant by restricted mean 
survival analysis at 24 months (mean difference=-3.3, 95%CI, -6.4- -0.1; p=0.04), 
with no difference in the cohort with no detectable ESR1 mutation (mean difference=-
0.8 95%CI,-2.5-0.9; p=0.35). The estimated rates of overall survival at one-year in 
patients with ESR1 mutation detected was 62% (45%-75%) on exemestane and 80% 
(68%-87%) on fulvestrant (one year landmark analysis HR=0.50 95% CI,0.24-1.04, 
p=0.06, Figure 3). In patients without ESR1 mutations detected the one-year overall 
survival was 79% (71%-85%) on exemestane and 81% (74%-87%) on fulvestrant 
(p=0.75, Figure 3). 
 
Discussion 
We conducted a combined analysis of EFECT and SoFEA to investigate the clinical 
impact of ESR1 mutation analysed in circulating tumor DNA. Patients with ESR1 
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mutations detected had shorter progression-free survival when treated with 
exemestane therapy, compared with fulvestrant, and also had shorter overall survival 
in restricted mean survival analysis. Analysis of overall survival in patients with ESR1 
mutations suggested non-proportional hazards, suggesting that patients treated with 
ESR1 mutant cancers were at elevated risk of early death if treated with 
exemestane. Although hormone receptor positive breast cancer is generally indolent, 
this may suggest that treatment with an inactive hormone therapy has potential short-
term risks for patients, in a subset of patients where ESR1 mutant breast cancer may 
behave more aggressively[12].   
 
In routine clinical practice exemestane is now frequently given in combination with 
everolimus[13], potentially limiting the direct translation of these findings to routine 
practice. However, analysis of ESR1 mutations in BOLERO2 also suggested adverse 
outcome for patients with ESR1 mutations detected in baseline plasma[6]. 
Everolimus has activity when given with multiple different endocrine therapy 
backbones. Fulvestrant plus everolimus showed substantial activity in the phase II 
MANTA trial, with 12.2 months progression-free survival (95%CI,7.5–14.3)[14], and 
tamoxifen plus everolimus showed substantial activity in the phase II TamRAD trial 
with 8.6 months progression-free survival (95%CI,5.9-13.9)[15]. In an exploratory 
analysis of the TamRAD study, there was an overall survival improvement with 
tamoxifen plus everolimus (HR=0.45, 95%CI,0.24-0.84, P=0.007)[15]. In contrast, in 
BOLERO2 exemestane plus everolimus did not demonstrate a statistically significant 
improvement  (HR=0.89, 95%CI,0.73-1.10; P=0.14)[16]. Although TamRAD was a 
relatively small phase II study, we speculate that the overall survival results of 
exemestane plus everolimus were undermined by inactivity of exemestane in ESR1 
mutant breast cancer, and that tamoxifen backbone therapy had sufficient activity in 
ESR1 mutant breast cancer to mitigate this effect. Along with the unequivocal pre-
clinical evidence that ESR1 mutant cancer is resistant to oestrogen deprivation[17, 
18], our data suggests that exemestane plus everolimus should be used cautiously in 
patients with ESR1 mutations detected in ctDNA, and instead either fulvestrant or 
tamoxifen could be considered as alternative backbone endocrine therapy. In 
exploratory analysis, patients with different ESR1 mutations detected in ctDNA had 
similar improvement of outcome on fulvestrant versus exemestane (Supplementary 
Figure 5). Although patients with polyclonal ESR1 mutations in this data set had 
numerically improved outcome on fulvestrant compared to monoclonal ESR1 
mutations (Supplementary Figure 6), this analysis is limited by small numbers, and 
other data sets have not shown improved outcome of polyclonal versus monoclonal 
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on fulvestrant[19]. In the future further investigation of whether different ESR1 
mutations have differing responsiveness to fulvestrant, or tamoxifen, will be useful in 
this regard[18]. 
 
 
It is important to emphasise that patients treated with fulvestrant in EFECT and 
SoFEA were treated with a dose half that used currently, fulvestrant 250mg versus 
fulvestrant 500mg in the CONFIRM study[20], and this has important implications for 
interpreting the results of patients with undetected ESR1 mutations. Although there 
was no difference between exemestane and fulvestrant (Figure 2 and 3) in the ESR1 
undetected group, this may simply reflect the lower dose of fulvestrant used; it is 
likely reasonable to speculate that such patients treated with fulvestrant may have 
had improved PFS on fulvestrant 500mg compared with exemestane[20]. One other 
point from our results is that if post-AI a clinician is considering prescribing fulvestrant 
500mg there is likely no utility in assessing ESR1 mutations at that point.  AI therapy 
is currently stopped at progression in routine clinical practice. Given the potential 
efficacy of exemestane in ESR1 wild-type breast cancer, our findings suggest the 
possibility that AI therapy may have activity if continued in subsequent lines of 
therapy in ESR1 wild-type tumors. However, prospective trials would be required to 
validate this hypothesis. 
 
There are limitations to our analysis when considering potential clinical application. 
Although we provide evidence that ESR1 mutation ctDNA analysis has predictive 
and clinical utility, this was with a specific droplet digital PCR ESR1 mutation ctDNA 
assay, with analysis conducted in one central laboratory. It is unknown the extent to 
which these results would be reproduced by different ctDNA assays, and in different 
laboratories. In prior work we have shown high reproducibility between the digital 
PCR assay used in this manuscript and BEAMing digital PCR[21], providing 
evidence of inter-assay agreement when conducted in central laboratories. Further 
research is required on the widespread clinical application of such assays. In EFECT 
we analysed serums samples, which is in general an inferior sample type for ctDNA 
analysis due to white blood cell lysis releasing contaminating DNA during blood 
clotting[11]. The rate of detection of ESR1 mutations was not affected by total DNA 
amounts (Supplementary figure 1), suggesting this contamination did not affect the 
results. The rate of ESR1 mutations was modestly lower in EFECT serum analysis 
(23.4%,52/222) compared to SOFEA plasma analysis (39.1%,63/161), possibly 
reflecting lower sensitivity, or reflecting different study populations such as the 
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inclusion of intrinsically endocrine resistant patients in EFECT, which are known to 
have a lower incidence of ESR1 mutations[3]. No patients in SOFEA or EFECT had 
prior exposure to CDK4/6 inhibitors. Patients on CDK4/6 inhibitor and AI also acquire 
ESR1 mutations, possibly at approximately the same incidence to patients on AI 
alone, although an accurate incidence has not yet been established [22, 23]. This 
suggests our findings will be equally relevant in deciding second line endocrine 
therapy backbone now that CDK4/6 inhibitors are a standard of care. 
 
In conclusion, we demonstrate that the detection of ESR1 mutations in baseline 
metastatic breast cancer circulating tumor DNA analysis predicts lack of benefit from 
subsequent aromatase inhibitor therapy. Patients with ESR1 mutations acquired 
through prior AI therapy have both adverse progression-free and overall survival 
when treated with exemestane. Our data provides evidence of clinical utility of ctDNA 
liquid biopsies in breast cancer, suggesting the potential to improve outcome to 
monitor for the presence of ESR1 mutations in advanced breast cancer, to aid in 
selection of the most appropriate subsequent endocrine therapy backbone, if further 
aromatase inhibitor-based therapy is being considered. 
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Table 1. Baseline characteristics associated with ESR1 mutation detection in 
baseline ctDNA. 
  
 
ESR1 
mutant 
ESR1 
wildtype 
 
N=115 N=268 
Age at randomisation (years); p=0.09 N (%) N (%) 
<50 11 (9.6)    15 (5.6)  
50-64 57 (49.6) 115 (42.9)  
65-75 29 (25.2) 92 (34.3)  
≥75 18 (15.7) 46 (172) 
 
    
Hormone receptor status; p=0.88      
ER+, PgR+  68 (59.1)  151 (56.3)  
ER+, PgR- 22 (19.1)  57 (21.3)  
ER+, PgR unknown  22 (19.1)  51 (19.0)  
ER-/unknown, PgR+  1 (0.9)  5 (1.9)  
ER unknown, PgR unknown  2(1.7)  2 (0.8)  
ER-, PgR- 0 (0.0) 2 (0.8) 
 
    
Visceral involvement; p=0.31  73 (63.5)  155 (57.8)  
Yes  42 (36.5) 113 (42.2) 
No     
 
    
Site of disease; p=0.13     
Visceral  73 (63.5)  155 (57.8)  
Soft tissue/node  20 (17.4)  73 (27.2)  
Bone only  22 (19.1)  39 (14.6) 
Unknown 0 (0.0)  1 (0.4) 
 
    
Time from diagnosis to randomisation (years); p=0.96      
<1 0 (0.0)  9 (3.4)  
1-2 25 (21.7) 43 (16.0)  
3-4 16 (13.9)  42 (15.7)  
5+ 74 (64.4) 174 (64.9) 
 
    
NSAI setting & time on NSAI; p=0.01      
Adjuvant  15 (13.0)  47 (17.5)  
ABC <1 year  14 (12-2)  63 (23.5)  
ABC 1-2 years  37 (32.2)  68 (25.4)  
ABC 2+ years  49 (42.6)  87 (32.5)  
Unknown 0 (0.0) 3 (1.1) 
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Al status; p=0.02      
Sensitive  96 (83.5)  194 (72.4)  
Resistant 19 (16.5) 74 (27.6) 
 
ER – oestrogen receptor; PgR – progesterone receptor; ABC – advanced breast 
cancer; NSAI – non steroidal aromatase inhibitor; AI status – sensitivity to prior 
aromatase inhibitor (sensitive indicating relapse after at least 2 years adjuvant AI or 
response or duration of stable disease lasting at least 24 weeks in the metastatic 
setting). P values from Chi-squared test. 
 
 
Table 2. Multivariable analysis of progression free survival in the SoFEA and 
EFECT combined analysis  
 
  
    
Hazard ratio (95% 
CI) p value 
ESR1 mutation status Wild type  1 - 
 
Mutant 1.96 (1.34, 2.86) 0.001 
 
    
 Treatment group Exemestane  1 - 
 
Fulvestrant 1.08 (0.82, 1.41) 0.6 
 
    
 Age at randomisation <50 1 - 
 
50-64  0.88 (0.56, 1.37)  0.56 
 
65-75  0.69 (0.44, 1.11)  0.13 
 
≥75 0.55 (0.33, 0.91) 0.02 
 
    
 Site of disease Visceral 1 - 
 
Soft tissue/node  0.76 (0.58,0.99)  0.04 
 
Bone only 0.65 (0.46, 0.90) 0.01 
 
    
 Time from diagnosis <1 year  1 - 
 to randomisation 1-2 years  0.58 (0.28, 1.19)  0.13 
 
3-4 years 0.59 (0.28, 1.22)  0.15 
 
 5+ years 0.45 (0.22, 0.90) 0.02 
 
    
 Hormone receptor status ER+, PgR+  1 - 
 
ER+, PgR- 0.91 (0.69, 1.20)  0.5 
 
ER+, PgR unknown  0.69 (0.50, 0.94)  0.02 
 
ER-/unknown, PgR+ 0.51 (0.16, 1.62) 0.25 
 
    
 ESR1 mutation status   0.61 (0.38, 1.00) 0.05 
X Treatment group (interaction)     
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 ER – oestrogen receptor; PgR – progesterone receptor; ABC – advanced breast 
cancer. 
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Figure 1. CONSORT diagram of EFECT and SoFEA combined analysis. 
 
 
 
Figure 2. Progression free survival in the combined analysis of SoFEA and 
EFECT by ESR1 mutation status and treatment. 
Patients with ESR1 mutation detected HR=0.59, 95%CI,0.39, 0.89; p=0.01. Patients 
without ESR1 mutation detected HR=1.05, 95%CI,0.81, 1.37; p=0.69.  Interaction 
test p=0.02. E – exemestane, F – fulvestrant, Mutant – ESR1 mutation detected, Wild 
type – ESR1 mutation not detected. 
 
 
 
Figure 3. Overall survival in the combined analysis of SoFEA and EFECT by 
ESR1 mutation status and treatment.  
Patients with ESR1 mutation detected, restricted mean survival analysis p=0.04.  For 
patients without ESR1 mutation detected, restricted mean survival analysis p=0.69. E 
– exemestane, F – fulvestrant, Mutant – ESR1 mutation detected, Wild type – ESR1 
not detected. 
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